# EDGAR Filing Document

**Accession Number:** 0002022416
**File Stem:** 0001178913-25-003198
**Filing Date:** 2025-9
**Character Count:** 2479
**Document Hash:** adb36221b79cd73bdcebcb1d41bc851d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001178913-25-003198.hdr.sgml**: 20251120

**ACCESSION NUMBER**: 0001178913-25-003198

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250902

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Silexion Therapeutics Corp
- **CENTRAL INDEX KEY:** 0002022416
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 12 ABBA HILLEL ROAD
- **CITY:** RAMAT GAN
- **STATE:** L3
- **ZIP:** 5250606
- **BUSINESS PHONE:** 972-8-6286005

**MAIL ADDRESS:**
- **STREET 1:** 12 ABBA HILLEL ROAD
- **CITY:** RAMAT GAN
- **STATE:** L3
- **ZIP:** 5250606

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Biomotion Sciences
- **DATE OF NAME CHANGE:** 20240506

------

![](image0.jpg)

Silexion Therapeutics Corp<br> 12 Abba Hillel Road

Ramat Gan, Israel 5250606

Telephone: +972-3-756499

September 2, 2025

#### <br>

#### VIA EDGAR
U.S. Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences100 F Street, NE

Washington, DC 20549

Attention:<br>Division of Corporation Finance, Daniel Crawford

---

| | |
|:---|:---|
| Re: | **Silexion Therapeutics Corp** |
|  | **Registration Statement on Form S-1** |
|  | **Filed August 26, 2025**<br> **SEC File Number 333-289860** |

---

Dear Mr. Crawford:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Silexion Therapeutics Corp hereby requests that the effective date of the above-referenced Registration Statement on Form S-1 be accelerated so that it will become effective at 9:00 a.m. Eastern Time on Thursday, September 4, 2025, or as soon as practicable thereafter.

Please contact Jonathan M. Nathan, Adv., at Meitar Law Offices, our outside (Israeli) legal counsel, at +972-52-312-5574 or jonathann@meitar.com, with any questions, and please notify him when this request for acceleration has been granted.

---

| |
|:---|
| Sincerely, |
| /s/ Ilan Hadar |
| Ilan Hadar |
| Chief Executive Officer |

---

CC: Daniel Crawford *Securities and Exchange Commission<br>* <br> Mirit Horenshtein Hadar <br> *Silexion Therapeutics Corp*

<br> Gary Emmanuel, Esq. *Greenberg Traurig, LLP* ** <br> *Jonathan M. Nathan, Adv. *Meitar Law Offices** 

------